| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group SF Barrington, NG Mikhaeel, L Kostakoglu, M Meignan, M Hutchings, ... Journal of clinical oncology 32 (27), 3048-3058, 2014 | 1660 | 2014 |
| Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage … A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ... Journal of clinical oncology 25 (24), 3746-3752, 2007 | 1029 | 2007 |
| FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma M Hutchings, A Loft, M Hansen, LM Pedersen, T Buhl, J Jurlander, S Buus, ... Blood 107 (1), 52-59, 2006 | 925 | 2006 |
| Early positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial MPE André, T Girinsky, M Federico, O Reman, C Fortpied, M Gotti, ... Journal of Clinical Oncology 35 (16), 1786-1794, 2017 | 501 | 2017 |
| FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma NG Mikhaeel, M Hutchings, PA Fields, MJ O'Doherty, AR Timothy Annals of oncology 16 (9), 1514-1523, 2005 | 500 | 2005 |
| Omitting radiotherapy in early positron emission tomography–negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the … JMM Raemaekers, MPE Andre, M Federico, T Girinsky, R Oumedaly, ... Journal of clinical oncology 32 (12), 1188-1194, 2014 | 447 | 2014 |
| Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma M Hutchings, NG Mikhaeel, PA Fields, T Nunan, AR Timothy Annals of oncology 16 (7), 1160-1168, 2005 | 434 | 2005 |
| Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up DA Eichenauer, BMP Aleman, M André, M Federico, M Hutchings, ... Annals of Oncology 29, iv19-iv29, 2018 | 422 | 2018 |
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ... Annals of Oncology 28 (7), 1436-1447, 2017 | 346 | 2017 |
| Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography–staged treatment-naive patients with Hodgkin lymphoma TC El-Galaly, F d'Amore, KJ Mylam, P de Nully Brown, M Bøgsted, A Bukh, ... Journal of clinical oncology 30 (36), 4508-4514, 2012 | 336 | 2012 |
| International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ... Journal of Nuclear Medicine 54 (5), 683-690, 2013 | 335 | 2013 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959-1970, 2021 | 322 | 2021 |
| Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma M Hutchings, A Loft, M Hansen, LM Pedersen, AK Berthelsen, S Keiding, ... haematologica 91 (4), 482-489, 2006 | 322 | 2006 |
| Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic … T Terasawa, J Lau, S Bardet, O Couturier, T Hotta, M Hutchings, T Nihashi, ... Journal of Clinical Oncology 27 (11), 1906-1914, 2009 | 315 | 2009 |
| The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ... Haematologica 99 (6), 1107, 2014 | 292 | 2014 |
| PET/CT for therapy response assessment in lymphoma M Hutchings, SF Barrington Journal of nuclear medicine 50 (Suppl 1), 21S-30S, 2009 | 283 | 2009 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 276 | 2022 |
| Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up DA Eichenauer, A Engert, M André, M Federico, T Illidge, M Hutchings, ... Annals of oncology 25, iii70-iii75, 2014 | 273 | 2014 |
| Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... The Lancet 398 (10306), 1157-1169, 2021 | 236 | 2021 |
| Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial C Thieblemont, T Phillips, H Ghesquieres, CY Cheah, MR Clausen, ... Journal of Clinical Oncology 41 (12), 2238-2247, 2023 | 223 | 2023 |
Chan CheahSir Charles Gairdner Hospital and University of Western AustraliaVerified email at health.wa.gov.au
